Trends in breast cancer incidence among women with type-2 diabetes in British general practice

2017 ◽  
Vol 11 (4) ◽  
pp. 373-382 ◽  
Author(s):  
Heleen K. Bronsveld ◽  
Paul J.H.L. Peeters ◽  
Mark C.H. de Groot ◽  
Anthonius de Boer ◽  
Marjanka K. Schmidt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
General Practice ◽  
Cancer Incidence ◽  
Breast Cancer Incidence

Breast cancer incidence before and after diagnosis of type 2 diabetes mellitus in women

2014 ◽  
Vol 23 (2) ◽  
pp. 76-83 ◽  
Author(s):  
Adedayo A. Onitilo ◽  
Rachel V. Stankowski ◽  
Richard L. Berg ◽  
Jessica M. Engel ◽  
Ingrid Glurich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Before And After

scholarly journals Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes

2019 ◽  
Vol 175 (3) ◽  
pp. 741-748 ◽  
Author(s):  
Mayu Hosio ◽  
Elina Urpilainen ◽  
Mikko Marttila ◽  
Ari Hautakoski ◽  
Martti Arffman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
Cancer Incidence ◽  
Breast Cancer Incidence ◽  
Antidiabetic Medication

scholarly journals The Relation of Type 2 Diabetes and Breast Cancer Incidence in Asian, Hispanic and African American Populations—A Review

2018 ◽  
Vol 42 (1) ◽  
pp. 100-105 ◽  
Author(s):  
Gertraud Maskarinec ◽  
Angelique Fontaine ◽  
Johanna Eyrun Torfadottir ◽  
Lorraine L. Lipscombe ◽  
Iliana C. Lega ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
African American ◽  
Cancer Incidence ◽  
Breast Cancer Incidence

Human insulin to increase breast cancer risk in Taiwanese women with type 2 diabetes.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 26-26
Author(s):  
Chin-Hsiao Tseng
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
Human Insulin ◽  
Cumulative Dose ◽  
Breast Cancer Incidence ◽  
Diabetic Patients ◽  
Hazard Ratios ◽  
Taiwanese Women ◽  
Cumulative Duration

26 Background: To investigate whether human insulin use may be associated with risk of breast cancer in Taiwanese women with type 2 diabetes. Methods: The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2004 and a total of 482,065 women with type 2 diabetes were followed up for breast cancer incidence until the end of 2009. Incidences for ever-users, never-users and subgroups of human insulin exposure (using tertile cutoffs of time since starting insulin, cumulative dose and cumulative duration of insulin) were calculated and the multivariable-adjusted hazard ratios were estimated by Cox regression. Results: There were 59,830 ever-users and 422,235 never-users, with respective numbers of incident breast cancer of 559 (0.93%) and 4,711 (1.12%), and respective incidence of 207.7 and 215.1 per 100,000 person-years. The overall adjusted hazard ratios (95% confidence intervals) did not show a significant association with insulin [1.098 (0.994-1.212)]. However, significant trends for the different categories of the dose-responsive parameters were observed. Patients in the third tertiles consistently showed a significantly higher risk of breast cancer while compared to never-users: 1.263 (1.093-1.458), 1.339 (1.164-1.540) and 1.331 (1.158-1.531) for ≥ 67 months for time since starting insulin, ≥ 39,000 units for cumulative dose of insulin, and ≥ 21.8 months for cumulative duration of insulin, respectively. Conclusions: This study discloses a significantly higher risk of breast cancer associated with the use of human insulin, demonstrating a significant dose-responsive relationship.

Effect of human insulin on breast cancer risk in Taiwanese women with type 2 diabetes.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 43-43
Author(s):  
Chin-Hsiao Tseng
Keyword(s):  
Breast Cancer ◽  
Type 2 Diabetes ◽  
Human Insulin ◽  
Cumulative Dose ◽  
Cox Regression ◽  
Breast Cancer Incidence ◽  
Hazard Ratios ◽  
Patients With Diabetes ◽  
Cumulative Duration

43 Background: Whether human insulin may induce breast cancer is rarely studied. Methods: The reimbursement databases of all Taiwanese patients with diabetes from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at January 1, 2004 and a total of 482,065 women with type 2 diabetes were followed up for breast-cancer incidence until the end of 2009. Incidences for ever-users, never-users, and subgroups of human insulin exposure (using tertile cutoffs of cumulative dose and cumulative duration of insulin) were calculated and the multivariable-adjusted hazard ratios were estimated by Cox regression. Results: There were 59,830 ever-users and 422,235 never-users, with respective numbers of incident breast cancer of 559 (0.93%) and 4,711 (1.12%), and respective incidence of 207.7 and 215.1 per 100,000 person-years. The overall adjusted hazard ratios (95% confidence intervals) did not show a significant association with insulin [1.098 (0.994-1.212)]. However, significant trends for the different categories of the dose-responsive parameters were observed. Patients in the third tertiles consistently showed a significantly higher risk of breast cancer compared to never-users: 1.339 (1.164-1.540) and 1.331 (1.158-1.531) for ≥ 39,000 units for cumulative dose of insulin, and ≥ 21.8 months for cumulative duration of insulin, respectively. Conclusions: This study discloses a significantly higher risk of breast cancer associated with the use of human insulin, demonstrating a significant dose-responsive relationship.

Sign in / Sign up

Export Citation Format

Share Document